Overexpression of NEK2 is observed in a number of cancers including breast cancer, pancreatic cancer, lung adenocarcinoma, cholangiocarcinoma, colorectal cancer (CRC) and non-Hodgkin lymphoma [12–18]. This evidence concerns the gene NEK2 and breast carcinoma.